Epizyme, Inc. EPZM
Set alert
As of Apr 24, 3:47 PM ET
52-week range unavailable
- Open
- 1.49
- Prev close
- 1.47
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.47
- High
- 1.50
- Forward P/E
- -0.67
- Beta
- -0.42
- Short ratio
- 0.78
- Inst. own
- 81.05%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2022
- 50-d avg
- 1.25
- 200-d avg
- 1.67
- 1y target
- 6.00
News
3 years ago globenewswire.com
Ipsen to acquire Epizyme, expanding its portfolio in oncology
PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under…
3 years ago globenewswire.com
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022
PARIS, FRANCE, 5 August 2022 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration…
3 years ago globenewswire.com
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to…
4 years ago businesswire.com
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive…
4 years ago zacks.com
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y
Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.
4 years ago zacks.com
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
4 years ago businesswire.com
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients…
4 years ago businesswire.com
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the…
4 years ago businesswire.com
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc.…
4 years ago headlinesoftoday.com
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
NEW YORK, July 6, 2022 /PRNewswire/ — If you own shares in any of the companies listed above and would like to discuss our investigations or have any...
4 years ago newsfilecorp.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Epizyme, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating Epizyme, Inc. ("Epizyme") (NASDAQ: EPZM) regarding possible breaches of fiduciary duties and other…
-
4 years ago benzinga.com
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade.
4 years ago prnewswire.com
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM
NEW YORK , June 27, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm…
4 years ago prnewswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.
NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. ("Epizyme" or the…
-
4 years ago benzinga.com
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade.
4 years ago fool.com
Why Epizyme Stock Is Soaring Today
A buyout ends Epizyme's 15-year tenure as an independent biopharma.
4 years ago prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen
MILWAUKEE , June 27, 2022 /PRNewswire/ -- Ademi LLP is investigating Epizyme (NASDAQ:EPZM) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click…
4 years ago businesswire.com
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Epizyme, Inc. (NASDAQ: EPZM) to Ipsen is fair to Epizyme shareholders. Halper Sadeh…
4 years ago benzinga.com
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share. The deal is expected to…
4 years ago businesswire.com
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology
PARIS & CAMBRIDGE, MASS.--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today…
4 years ago zacks.com
Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows.
-
4 years ago benzinga.com
99 Biggest Movers From Yesterday
Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows.
-
4 years ago benzinga.com
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
4 years ago benzinga.com
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter.
-
4 years ago benzinga.com
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows.
-
4 years ago benzinga.com
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
4 years ago benzinga.com
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.
-
4 years ago benzinga.com
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 136 companies reached new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 207 companies hit new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning session, 216 companies made new 52-week lows.
-
5 years ago benzinga.com
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
-
5 years ago benzinga.com
Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop
Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81.
-
5 years ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
5 years ago benzinga.com
Mid-Day Market Update: Pro-Dex Rises After Q3 Results; Orphazyme Shares Slide
Midway through trading Friday, the Dow traded up 0.45% to 34,705.48 while the NASDAQ rose 1.35% to 13,816.46. The S&P also rose, gaining 0.77% to 4,233.93.
-
5 years ago benzinga.com
56 Stocks Moving In Friday's Mid-Day Session
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares jumped 77% to $4.321.